TP53 and cancer: Mutations in TP53 are among the most frequent somatic aberrations in human cancers and are frequently reported as a negative prognostic factor for survival in many solid tumour types, including lung [45], colorectal [46], breast [47], and prostate carcinoma [48], irrespective of systemic therapy.